Market Overview

Attention Bluebird Bio Investors: Analyst Sees Upside Following Strong Therapy Results

Attention Bluebird Bio Investors: Analyst Sees Upside Following Strong Therapy Results
Related BLUE
Benzinga's Top Upgrades, Downgrades For August 17, 2017
Benzinga's Top Upgrades, Downgrades For July 27, 2017

Citing the release of new bb2121 therapy data among other growth factors, BMO analyst Matthew Luchini has upgraded bluebird bio Inc (NASDAQ: BLUE) to Outperform and raised his price target to $108.

“We believe latest data shows bb2121's continued compelling efficacy, including 100 percent ORR rate, and a generally clean safety profile in a heavily pretreated 3L+ myeloma population,” Luchini said. “We see additional opportunity for near-term upside in BLUE with the upcoming EHA meeting (June 22–25).”

Key Takeaways

Bb2121, an anti-BCMA CAR-T therapy for multiple myeloma, is performing extremely well compared the efficacy report by the current SOC daratumumab. The report also highlighted that the drug was even tested in a very difficult population (patients had a median of seven prior therapies) and still performed well.

Key Metrics for bb2121

    Response rate: 100 percent
    Number of patients relapsing: zero
    Patients reporting complete response: 27 percent
    Patients reporting very good partial response: 47 percent
    Toxicities that appear manageable: all

Moving Forward

Luchini is now looking ahead “for the next update later in 2017, likely at ASH (December 9–12), and for Bluebird Bio to move forward with a pivotal trial under breakthrough designation.


Additionally, bb21217, Bluebird Bio’s second-generation BCMA program, could offer further upside. “We believe having two BCMA-focused products could allow BLUE to more effectively segment the myeloma market and also potentially have more flexibility in pricing, with bb2121 potentially focused on highly refractory patients, while bb21217 could be used in less severe population and at a lower price,” Luchini said.

Bluebird Bio was trading up nearly 13 percent at $102.55 during Tuesday’s trading session.

Related Links:

BlueBird Bio Wounded After Roth Downgrade

Your Cheat Sheet For Q1 Biotech Earnings

Latest Ratings for BLUE

Aug 2017Evercore ISI GroupInitiates Coverage OnIn-Line
Aug 2017Morgan StanleyMaintainsEqual-Weight
Jul 2017BernsteinInitiates Coverage OnMarket Perform

View More Analyst Ratings for BLUE
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Price Target Reiteration Analyst Ratings Movers Best of Benzinga


Related Articles (BLUE)

View Comments and Join the Discussion!